专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2004269520A PEPTIDE DEACTIVATING ANAPHYLATOXIN C5a 有权
公开(公告)号：JP2004269520A
公开(公告)日：2004-09-30
申请号：JP2004044012
申请日：2004-02-20
申请人： Hidechika Okada , Noriko Okada , 則子岡田 , 秀親岡田
发明人： OKADA HIDECHIKA , OKADA NORIKO , FUJITA EMIKO
IPC分类号： A61K38/00 , A61P9/00 , A61P29/00 , A61P37/00 , A61P37/08 , A61P43/00 , C07K7/08
摘要： PROBLEM TO BE SOLVED: To provide a treating and prophylactic agent for an inflammatory disease, which contains a peptide deactivating an anaphylatoxin C5a as an active ingredient.
SOLUTION: A peptide complementary to the peptide part consisting of the amino-terminal number 37-53 amino acids of a complement fragment C5a is structurally designed and synthesized to give a peptide deactivating an anaphylatoxin activity of C5a by binding with C5a.
COPYRIGHT: (C)2004,JPO&NCIPI

2. 发明专利

JP2004262910A Thrombomodulin-inactivating peptide 审中-公开
公开(公告)号：JP2004262910A
公开(公告)日：2004-09-24
申请号：JP2003102267
申请日：2003-02-28
申请人： Hidechika Okada , Noriko Okada , 則子岡田 , 秀親岡田
发明人： OKADA HIDECHIKA , OKADA NORIKO , SHIMOMURA YASUYO
IPC分类号： A61K38/00 , A61P9/00 , A61P29/00 , A61P37/08 , C07K7/08
摘要： PROBLEM TO BE SOLVED: To provide a preventing and treating agent of inflammatory morbid state, thrombosis, etc., by using a peptide inactivating thrombomodulin as an active ingredient.
SOLUTION: This peptide inhibiting the activity of the trombomodulin for reinforcing the activity of thrombin is created by designing/synthesizing a complemental peptide against a part of thrombobodulin from 408th glutamine to 426th glutamic acid of the thrombomodulin and performing the reaction with thrombomodulin.
COPYRIGHT: (C)2004,JPO&NCIPI

3. 发明申请

US20100015221A1 ORALLY RAPID DISINTEGRATING TABLET PREPARATION COMPRISING FAT-SOLUBLE ACTIVE INGREDIENTS 审中-公开
标题翻译：可快速消除包含脂肪可溶性活性成分的片剂制剂
公开(公告)号：US20100015221A1
公开(公告)日：2010-01-21
申请号：US12097867
申请日：2006-12-20
申请人： Norishige Takami , Shinsuke Nagira , Yasushi Okada , Noriko Okada , Takayuki Ohwaki , Reiko Nishijima
发明人： Norishige Takami , Shinsuke Nagira , Yasushi Okada , Noriko Okada , Takayuki Ohwaki , Reiko Nishijima
IPC分类号： A61K9/20 , A61K31/07 , A61K31/59 , A61K31/122 , A61K31/121 , A61K31/355 , A61P43/00
CPC分类号： A61K9/2054 , A61K9/0056 , A61K9/16 , A61K9/2018 , A61K9/2077 , A61K31/07 , A61K31/121 , A61K31/122 , A61K31/355 , A61K31/59
摘要： The present invention provides an orally rapid disintegrating tablet preparation that contains a high dose of a fat-soluble active ingredient, that exhibits excellent disintegration characteristics in the oral cavity, and that can be produced by a dry tabletting method. The present invention also provides a method of producing an orally rapid disintegrating tablet preparation. The present invention discloses an orally rapid disintegrating tablet preparation that is obtained by tabletting a uniform mixture prepared by mixing saccharide alcohol, crystalline cellulose, and a lubricant with a granule that has been produced by the adsorption of a fat-soluble active ingredient on a porous material.
摘要翻译：本发明提供一种口服快速崩解片剂，其含有高剂量的在口腔中具有优异的崩解特性的脂溶性活性成分，并且可以通过干燥压片法制造。本发明还提供一种口服快速崩解片剂的制备方法。本发明公开了一种口服快速崩解片剂，其通过将通过将脂溶性活性成分吸附在多孔性物质上制成的颗粒将糖醇，结晶纤维素和润滑剂混合而成的均匀混合物材料。

4. 发明申请

US20060063701A1 Methods and compositions for modulating C5-a-mediated inflammatory responses 有权
标题翻译：调节C5-a介导的炎症反应的方法和组合物
公开(公告)号：US20060063701A1
公开(公告)日：2006-03-23
申请号：US11202449
申请日：2005-08-11
申请人： Hidechika Okada , Noriko Okada
发明人： Hidechika Okada , Noriko Okada
IPC分类号： A61K38/10 , C07K7/08
CPC分类号： C07K7/08 , A61K38/00 , C07K14/472
摘要： PL37 (RAARISLGPRICKAFTE [SEQ ID NO: 2]) is an Antisense Homolgoy Box peptide composed of amino acids 37 to 53 of C5a-anaphylatoxin. Complementary peptides, ASGAPAPGPAGPLRPMF (Pep-A [SEQ ID NO: 1]) and ASTAPARAGLPRLPKFF (Pep-B [SEQ ID NO: 3]) were designed and characterized. Pep-A bound to PL37 and to C5a with very slow dissociation, whereas Pep-B failed to bind at all. C5a was inactivated by 7 nM or more of Pep-A and this concentration of Pep-A inhibited induction of intracellular Ca++ influx in neutrophils. Patch clamp studies also showed the effectiveness of Pep-A in C5a-receptor-expressing neuroblastoma cells. Pep-A administration prevented rats from C5a-mediated rapid lethal shock. A-Pep-A (Pep-A acetylated with alanine at the amino-terminus) was more stable in vivo and showed stronger inhibition of inflammatory reactions in mice and rats. Chemical modification of Pep-A (e.g., acetylation, or single or multiple amino acid replacement, insertion, or deletion within the native Pep-A sequence) will yield effective inhibitors, and will often improve inhibitory function on C5a anaphylatoxin. In such modified constructs it will often be desired to conserve some or all 5 prolines found in Pep-A to preserve inhibitory function on C5a.
摘要翻译： PL37（RAARISLGPRICKAFTE [SEQ ID NO：2]）是由C5a-过敏毒素的氨基酸37至53组成的反义同源盒肽。设计并表征互补肽ASGAPAPGPAGPLRPMF（Pep-A [SEQ ID NO：1]）和ASTAPARAGLPRLPKFF（Pep-B [SEQ ID NO：3]）。 Pep-A与PL37和C5a结合非常缓慢的解离，而Pep-B根本无法结合。 C5a被7nM或更多的Pep-A灭活，并且该浓度的Pep-A抑制嗜中性粒细胞内细胞内Ca ++流入的诱导。补体钳研究还显示Pep-A在表达C5a受体的神经母细胞瘤细胞中的有效性。 Pep-A治疗阻止大鼠C5a介导的快速致死性休克。 A-Pep-A（在氨基末端用丙氨酸乙酰化的Pep-A）在体内更稳定，并且在小鼠和大鼠中表现出更强的炎症反应抑制。 Pep-A的化学修饰（例如，乙酰化，或天然Pep-A序列内的单个或多个氨基酸置换，插入或缺失）将产生有效的抑制剂，并且将经常改善对C5a过敏毒素的抑制功能。在这种修饰的构建体中，通常需要保存Pep-A中发现的一些或全部5个脯氨酸以保持对C5a的抑制功能。

5. 发明授权

US07595050B2 Human IGM monoclonal antibody capable of inducing apoptosis in HIV-infected cells 失效
标题翻译：能够诱导HIV感染细胞凋亡的人IGM单克隆抗体
公开(公告)号：US07595050B2
公开(公告)日：2009-09-29
申请号：US10519855
申请日：2003-06-30
申请人： Hidechika Okada , Noriko Okada
发明人： Hidechika Okada , Noriko Okada
IPC分类号： A61K39/42
CPC分类号： C07K16/28 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/73
摘要： A monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis is obtained. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contains as the active ingredient a human IgM antibody capable of specifically reacting with HIV-infected cells, inducing apoptosis in the infected cells and thus disrupting the cells, etc.
摘要翻译：属于特异性识别HIV感染细胞并诱导凋亡的人IgM类别的单克隆抗体。使用获得的抗体旨在为患有HIV感染的患者提供补救措施，其包含作为活性成分的能够与HIV感染的细胞特异性反应的人IgM抗体，诱导感染的细胞中的细胞凋亡，从而破坏细胞等

6. 发明申请

US20060292160A1 Human igm antibody inducing apotosis in hiv-infected cells and remedy for hiv-infection 失效
标题翻译：人igm抗体在HIV感染细胞中诱导凋亡，并用于HIV感染治疗
公开(公告)号：US20060292160A1
公开(公告)日：2006-12-28
申请号：US10519855
申请日：2003-06-30
申请人： Hidechika Okada , Noriko Okada
发明人： Hidechika Okada , Noriko Okada
IPC分类号： A61K39/42 , C07K16/10
CPC分类号： C07K16/28 , A61K2039/505 , C07K2317/21 , C07K2317/52 , C07K2317/73
摘要： A monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis is obtained. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contains as the active ingredient a human IgM antibody capable of specifically reacting with HIV-infected cells, inducing apoptosis in the infected cells and thus disrupting the cells, etc.
摘要翻译：属于特异性识别HIV感染细胞并诱导凋亡的人IgM类别的单克隆抗体。使用获得的抗体旨在为患有HIV感染的患者提供补救措施，其包含作为活性成分的能够与HIV感染的细胞特异性反应的人IgM抗体，诱导感染的细胞中的细胞凋亡，从而破坏细胞等

7. 发明申请

US20060275826A1 Artificial antibody comprising complementary peptide 审中-公开
标题翻译：包含互补肽的人工抗体
公开(公告)号：US20060275826A1
公开(公告)日：2006-12-07
申请号：US11414713
申请日：2006-04-28
申请人： Hidechika Okada , Noriko Okada
发明人： Hidechika Okada , Noriko Okada
IPC分类号： G01N33/53
CPC分类号： G01N33/6854 , C07K14/001 , C07K2318/20
摘要： A method for detecting an antigen using a complementary peptide reactive to a target protein as an artificial antibody.
摘要翻译：使用与靶蛋白反应的互补肽作为人造抗体来检测抗原的方法。

8. 发明授权

US06190863B1 Sugar chain-recognizing antibodies and remedies for HIV infectious diseases 失效
标题翻译：糖链识别抗体和HIV传染病的补救措施
公开(公告)号：US06190863B1
公开(公告)日：2001-02-20
申请号：US09077091
申请日：1998-05-19
申请人： Hidechika Okada , Noriko Okada
发明人： Hidechika Okada , Noriko Okada
IPC分类号： C12Q170
CPC分类号： C07K16/18 , A61K38/00 , A61K2039/505 , C07K16/28
摘要： The present invention is directed to a sugar-chain-recognizing antibody which belongs to the IgM isotype and which recognizes Gg4Cer(Gal&bgr;1-3GalNAc&bgr;1-4Gal&bgr;1-4Glc&bgr;Cer) or GM2 which appears on HIV infected cells, as well as to a therapeutics for HIV diseases containing those IgMs.
摘要翻译：本发明涉及属于IgM同种型并识别出现在HIV感染细胞上的Gg4Cer（Galbeta1-3GalNAcbeta1-4Galbeta1-4GlcbetaCer）或GM2的糖链识别抗体，以及用于HIV疾病的治疗剂含有这些IgM。

9. 发明授权

US5179198A Glycoprotein and gene coding therefor 失效
标题翻译： GLYCOPROTEIN及其基因编码
公开(公告)号：US5179198A
公开(公告)日：1993-01-12
申请号：US376828
申请日：1989-07-07
申请人： Hidechika Okada , Noriko Okada , Yoichi Nagami , Kazuhiro Takahashi , Hisao Takizawa , Jun Kondo
发明人： Hidechika Okada , Noriko Okada , Yoichi Nagami , Kazuhiro Takahashi , Hisao Takizawa , Jun Kondo
IPC分类号： A61K38/00 , C07K14/47 , C07K14/81 , C12N15/12
CPC分类号： C07K14/4703 , C07K14/8107 , A61K38/00 , Y10S530/827
摘要： The present invention provides a glycoprotein derived from human cell membrane, which has a molecular weight of 20 to 25 Kd as estimated by SDS polyacrylamide gel electrophoresis, and contains N-glycoside type carbohydrate chain and phosphatidylinositol, and possesses an inhibitory activity to complement-mediated cell membrane damage. The present invention further provides a gene coding for the glycoprotein, and a method for the production of the glycoprotein and the gene therefor.

10. 发明授权

US07914790B2 Human IgM antibody lysing activated lymphocytes under mediation by homologous complement 失效
标题翻译：人IgM抗体通过同源补体在调解下溶解活化的淋巴细胞
公开(公告)号：US07914790B2
公开(公告)日：2011-03-29
申请号：US10520016
申请日：2003-06-30
申请人： Hidechika Okada , Noriko Okada
发明人： Hidechika Okada , Noriko Okada
IPC分类号： A61K39/395 , C12N5/07
CPC分类号： C07K16/28 , A61K2039/505 , C07K2317/21 , C07K2317/56 , Y10S530/809
摘要： A human IgM monoclonal antibody responding to HIV-infected cells too, which is characterized by lysing activated human lymphocytes, etc. under the mediation by a homologous human complement, is obtained. Using the thus obtained monoclonal antibody, it is intended to provide an immune reaction controlling remedy, etc. containing the human IgM monoclonal antibody which responds specifically to activated lymphocytes and induces cell lysis under the mediation by a homologous complement. Using the human IgM monoclonal antibody responding to activated human lymphocytes, it is also intended to provide an HIV remedy, etc. characterized by lysing and eliminating activated lymphocytes to thereby treat transplantation rejection and autoimmune diseases caused by an over-response of T lymphocytes as well as HIV infection.
摘要翻译：获得了响应于HIV感染细胞的人IgM单克隆抗体，其特征在于通过同源人补体在介导下裂解活化的人淋巴细胞等。使用如此获得的单克隆抗体，旨在提供含有人IgM单克隆抗体的免疫反应控制药物，其特异性响应于活化的淋巴细胞，并在同源补体的介导下诱导细胞裂解。使用对活化的人淋巴细胞作出反应的人IgM单克隆抗体，还旨在提供HIV疗法等，其特征在于裂解和消除活化的淋巴细胞，从而治疗由T淋巴细胞过度反应引起的移植排斥反应和自身免疫性疾病作为艾滋病毒感染。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式